Professor of Medicine, University Tex Houston
Oncology
Dr. Gabriel N. Hortobagyi, MD
|
|
Give Review
Gabriel Hortobagyi is an expert in the field of Oncology. He received awards:"America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer", "Fellow (FASCO)", "Redbook Magazine: Top Breast Cancer Doctors" and "Super Doctor". Gabriel Hortobagyi is also a published physician. He has 100 paper published. The most recent paper is: Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
- Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience.
- Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast Cancer: a Bayesian network meta-analysis.
- The American Society of Clinical Oncology's Efforts to Support Global Cancer Medicine.
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Canc...
- Goserelin for ovarian protection during breast-Cancer adjuvant chemotherapy.
- Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.
- Hypofractionated whole Breast irradiation results in less acute toxicity and improved quality of life at six months compared to conventionally fractionated whole breas...
- Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast Cancer.
- SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer.
- Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes.
- Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.
- Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical On...
- Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast Cancer.
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast Cancer: overall survival results from BOLER...
- Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer.
- Effects of obesity on transcriptomic changes and Cancer hallmarks in estrogen receptor-positive breast Cancer.
- Leptomeningeal disease and breast Cancer: the importance of tumor subtype.
- Definition of PKC-α, CDK6 and MET as therapeutic targets in triple-negative breast Cancer.
- A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast Cancer cells through FOXO3-mediated Bim1 expression.
- Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500.
- Breast Cancer, BRCA Mutations, and Attitudes Regarding Pregnancy and Preimplantation Genetic Diagnosis.
- Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients ...
- Breast Cancer Subtype and Baseline Characteristics from Diabetic Breast Cancer Patients are Not Different from Nondiabetics.
- Predictors that Influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ Who Were Evaluated for BRCA Genetic Testing.
- Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer.
- Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment.
- Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up.
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast Cancer: insights from BOLERO-2.
- Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast Cancer.
- Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by ...
- Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast Cancer.
- Incidence, Risk Factors, and Management of Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab.
- Which threshold for ER positivity? A retrospective study based on 9639 patients.
- Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast Cancer.
- Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer.
- A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast Cancer: SWOG S0102.
- Differences in gene and protein expression and the effects of race/ethnicity on breast Cancer subtypes.
- Everolimus plus exemestane as first-line therapy in HR(+), HER2 (-) advanced breast Cancer in BOLERO-2.
- ESR1 ligand-binding domain mutations in hormone-resistant breast Cancer.
- Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.
- Effect of Age and Race On Quality of Life in Young Breast Cancer Survivors.
- Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer.
- TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase.
- Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast Cancer.
- Health-Related Quality of Life and Disease Symptoms in Postmenopausal Women With HR(+), HER2(-) Advanced Breast Cancer Treated With Everolimus Plus Exemestane Versus E...
- Differential response to neoadjuvant chemotherapy among 7 triple-negative breast Cancer molecular subtypes.
- Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast Cancer: Subgroup analysis from the BOLERO-2 study.
- Statin use in primary inflammatory breast Cancer: a cohort study.
- Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy.
- Clinical relevance of Cancer stem cells in bone marrow of early breast Cancer patients.
- Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast Cancer and impaired liver function secondary to hepatic metastases.
- Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP.
- Health-related quality of life of patients with advanced breast Cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomize...
- Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular Carcinomas.
- Impact of chemotherapy sequencing on local-regional failure risk in breast Cancer patients undergoing breast-conserving therapy.
- Supplement use during an intergroup clinical trial for breast Cancer (S0221).
- Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast Cancer.
- Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast Cancer containing tumorigenic CD49f(-) quiescent cells.
- Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
- Outcome of metastatic breast Cancer in selected women with or without deleterious BRCA mutations.
- Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management fo...
- Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast Cancer patients.
- USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer.
- Primary Tumor Extirpation in Breast Cancer Patients Who Present with Stage IV Disease is Associated with Improved Survival.
- Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic Breast ...
- Male breast Cancer according to tumor subtype and race : A population-based study.
- Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast Cancer.
- Genotype in BRCA-associated Breast Cancers.
- High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast Cancer patients.
- Functional proteomics characterization of residual breast Cancer after neoadjuvant systemic chemotherapy.
- A Prospective Study of Bone Tumor Response Assessment in Metastatic Breast Cancer.
- Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transpla...
- Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic bre...
- Targeting the IKKβ/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast Cancer.
- Concomitant targeting of tumor cells and induction of T cell response synergizes to effectively inhibit trastuzumab-resistant breast Cancer.
- Metformin and thiazolidinediones are associated with improved breast Cancer-specific survival of diabetic women with HER2+ breast Cancer.
- Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation ...
- Metastasis in the Breast Mimicking Inflammatory Breast Cancer.
- Retrospective review of male breast Cancer patients: analysis of tamoxifen-related side-effects.
- Decline in the Use of Anthracyclines for Breast Cancer.
- Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer.
- Circulating tumor cells in immunohistochemical subtypes of metastatic breast Cancer: lack of prediction in HER2-positive disease treated with targeted therapy.
- cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes.
- Identifying factors that impact survival among women with inflammatory breast Cancer.
- Epithelial-mesenchyme transition induced by TNF-a requires NF-kB mediated transcriptional upregulation of Twist1.
- Aromatase inhibitors and breast Cancer prevention.
- Gene expression, molecular class changes and pathway analysis after neoadjuvant systemic therapy for breast Cancer.
- Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer.
- Retrospective analysis of antitumor effects of zoledronic acid in breast Cancer patients with bone-only metastases.
- Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors.
- Short -term biomarker modulation prevention study of Anastrozole in Women at increased risk for second primary breast Cancer.
- Novel Staging System for Predicting Disease-Specific Survival in Patients With Breast Cancer Treated With Surgery As the First Intervention: Time to Modify the Current...
- Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast Cancer: long-term results.
- Is There an Ideal Way to Combine Trastuzumab With Chemotherapy?
- Hot Flashes: A Review of Pathophysiology and Treatment Modalities.
- A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast Cancer.
- Bevacizumab Treatment for Advanced Breast Cancer.
- Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast Cancer.
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Fellow (FASCO)
- Redbook Magazine: Top Breast Cancer Doctors
- Super Doctor
Education
-
University of Texas MD Anderson Cancer Center -
National University of Colombia
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1679668396 | |
| NPPES Provider LastName | HORTOBAGYI | |
| NPPES Provider FirstName | GABRIEL | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 173.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 6.36 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1679668396 |
| Last Name Of The Provider | HORTOBAGYI |
| First Name Of The Provider | GABRIEL |
| View All |
Similar Doctors
|
|
Dr. Lori A. Leslie, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fredrick B. Hagemeister, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James C. Yao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott M. Lippman, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Gerald S. Cyprus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jorge E. Romaguera, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jenny C. Chang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin J. Hrgovcic, MD |
|
|
Dr. Maria A. Scouros, MD
This Doctor is OpenDoctor Recommended.
|